These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

396 related items for PubMed ID: 16118771

  • 1. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.
    Scappaticci FA, Fehrenbacher L, Cartwright T, Hainsworth JD, Heim W, Berlin J, Kabbinavar F, Novotny W, Sarkar S, Hurwitz H.
    J Surg Oncol; 2005 Sep 01; 91(3):173-80. PubMed ID: 16118771
    [Abstract] [Full Text] [Related]

  • 2. "Spontaneous," delayed colon and rectal anastomotic complications associated with bevacizumab therapy.
    August DA, Serrano D, Poplin E.
    J Surg Oncol; 2008 Feb 01; 97(2):180-5. PubMed ID: 18095268
    [Abstract] [Full Text] [Related]

  • 3. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study.
    D'Angelica M, Kornprat P, Gonen M, Chung KY, Jarnagin WR, DeMatteo RP, Fong Y, Kemeny N, Blumgart LH, Saltz LB.
    Ann Surg Oncol; 2007 Feb 01; 14(2):759-65. PubMed ID: 17103075
    [Abstract] [Full Text] [Related]

  • 4. Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer.
    Thornton AD, Ravn P, Winslet M, Chester K.
    Br J Surg; 2006 Dec 01; 93(12):1456-63. PubMed ID: 17115389
    [Abstract] [Full Text] [Related]

  • 5. Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels.
    Brostjan C, Gebhardt K, Gruenberger B, Steinrueck V, Zommer H, Freudenthaler H, Roka S, Gruenberger T.
    Clin Cancer Res; 2008 Apr 01; 14(7):2065-74. PubMed ID: 18381946
    [Abstract] [Full Text] [Related]

  • 6. Review: incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer.
    Hompes D, Ruers T.
    Eur J Surg Oncol; 2011 Sep 01; 37(9):737-46. PubMed ID: 21764243
    [Abstract] [Full Text] [Related]

  • 7. Managing patients treated with bevacizumab combination therapy.
    Gordon MS, Cunningham D.
    Oncology; 2005 Sep 01; 69 Suppl 3():25-33. PubMed ID: 16301833
    [Abstract] [Full Text] [Related]

  • 8. [Surgical management of bevacizumab-associated peritonitis due to perforation].
    Kube R, Meyer F, Bien N, Schmidt C, Mroczkowski P, Dalicho S, Lippert H.
    Zentralbl Chir; 2009 Sep 01; 134(5):462-7. PubMed ID: 19757347
    [Abstract] [Full Text] [Related]

  • 9. Bevacizumab-associated fistula formation in postoperative colorectal cancer patients.
    Ganapathi AM, Westmoreland T, Tyler D, Mantyh CR.
    J Am Coll Surg; 2012 Apr 01; 214(4):582-8; discussion 588-90. PubMed ID: 22321523
    [Abstract] [Full Text] [Related]

  • 10. A review on bevacizumab and surgical wound healing: an important warning to all surgeons.
    Gordon CR, Rojavin Y, Patel M, Zins JE, Grana G, Kann B, Simons R, Atabek U.
    Ann Plast Surg; 2009 Jun 01; 62(6):707-9. PubMed ID: 19461291
    [Abstract] [Full Text] [Related]

  • 11. Managing patients with metastatic colorectal cancer on bevacizumab.
    Lemmens L, Claes V, Uzzell M.
    Br J Nurs; 2009 Jun 01; 17(15):944-9. PubMed ID: 18983014
    [Abstract] [Full Text] [Related]

  • 12. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T, Lindley C.
    Clin Ther; 2006 Nov 01; 28(11):1779-802. PubMed ID: 17212999
    [Abstract] [Full Text] [Related]

  • 13. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer.
    Cohen MH, Gootenberg J, Keegan P, Pazdur R.
    Oncologist; 2007 Mar 01; 12(3):356-61. PubMed ID: 17405901
    [Abstract] [Full Text] [Related]

  • 14. [Anti-angiogenic treatment and colorectal cancer].
    André T, Tournigand C, Abbas F, Louvet C, de Gramont A, Gercor (French Oncology Research Group).
    Bull Cancer; 2007 Jul 01; 94 Spec No():S211-9. PubMed ID: 17846007
    [Abstract] [Full Text] [Related]

  • 15. Fournier's gangrene as a possible side effect of bevacizumab therapy for resected colorectal cancer.
    Gamboa EO, Rehmus EH, Haller N.
    Clin Colorectal Cancer; 2010 Jan 01; 9(1):55-8. PubMed ID: 20100690
    [Abstract] [Full Text] [Related]

  • 16. Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer.
    Akun E, Okutur K, Seber S, Korkmaz T, Aydin K, Bozkurt M, Namal E, Hasbal B, Tecimer C, Demir G.
    J BUON; 2012 Jan 01; 17(4):669-76. PubMed ID: 23335523
    [Abstract] [Full Text] [Related]

  • 17. Safety of bevacizumab in metastatic breast cancer patients undergoing surgery.
    Cortés J, Caralt M, Delaloge S, Cortes-Funes H, Pierga JY, Pritchard KI, Bollag DT, Miles DW.
    Eur J Cancer; 2012 Mar 01; 48(4):475-81. PubMed ID: 22196033
    [Abstract] [Full Text] [Related]

  • 18. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events.
    Hurwitz H, Saini S.
    Semin Oncol; 2006 Oct 01; 33(5 Suppl 10):S26-34. PubMed ID: 17145522
    [Abstract] [Full Text] [Related]

  • 19. The effects of bevacizumab on postoperative complications in patients undergoing colorectal and pancreatic cancer resection.
    Cheon EC, Small W, Strouch MJ, Krantz SB, Rademaker A, Mulcahy MF, Benson AB, Bentrem DJ, Talamonti MS.
    J Surg Oncol; 2010 Oct 01; 102(5):539-42. PubMed ID: 20812264
    [Abstract] [Full Text] [Related]

  • 20. Indwelling central venous access port insertion during bevacizumab-based therapy.
    Grenader T, Goldberg A, Verstandig A, Shavit L.
    Anticancer Drugs; 2010 Aug 01; 21(7):704-7. PubMed ID: 20517148
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.